Adjusted versus actual body weight dosing of 4-factor prothrombin complex concentrate in obese patients with warfarin-associated major bleeding
The package insert of 4-factor prothrombin complex concentrate (4F-PCC) contains specific dosing recommendations stating to determine the patients dose based on their INR and weight, capping the weight at 100 kg. However, the mean body mass index (BMI) in the 4F-PCC U.S. approval study was 27 kg/m2, and there is a lack of literature identifying the ideal dosing strategy in obesity. We conducted a retrospective analysis of obese patients (BMI ≥ 30 kg/m2) who received 4F-PCC for warfarin associated emergent bleeding reversal. Treatment groups were those that received 4F-PCC on adjusted body weight (AdjBW) and those on actual body weight (ActBW). The primary outcome was the percent of patients achieving coagulopathy reversal, defined as a post-treatment INR < 1.4 for neurologic indications and < 1.5 for all others. A total of 78 obese patients were included (28 AdjBW and 50 ActBW). Baseline INR (3.1 vs. 2.8; p = 0.052) and BMI (33.6 vs. 33.6 kg/m2) were similar between groups. Achievement of goal INR was significantly lower in the AdjBW group (36% vs. 68%; p = 0.006). A majority of patients had intracranial hemorrhage (32% vs. 54%; p = 0.06), and the median dose of 4F-PCC was lower in the AdjBW group (2120 vs. 2500 units; p = 0.02). Dosing 4F-PCC using adjusted body weight in obese patients resulted in a significantly lower rate of coagulopathy reversal. ActBW should be used to dose 4F-PCC in obese patients when the 100 kg dose cap is utilized per the package insert recommendations.
KeywordsAnticoagulation therapy Hematology Hemorrhagic disorders Prothrombin Obesity
Study conception and design: KSS, RZ, CCM, MJE, ETVM, GMJ. Acquisition of data: KSS, RZ, CCM, MJE, GMJ. Analysis and interpretation of data: KSS, RZ, CCM, MJE, ETVM, GMJ. Critical revision of manuscript: KSS, RZ, CCM, MJE, ETVM, GMJ.
Compliance with ethical standards
Conflict of interest
All authors of this study have no direct or indirect conflicts of interest to disclose.
- 1.Ogden CLCM, Fryar CD, Flegal KM (2015) Prevalence of obesity among adults and youth: United States, 2011–2014. National Center for Health Statistics Data Brief Centers for Disease Control and Prevention, Washington, DCGoogle Scholar
- 3.Kcentra® [package insert] (2013) CSL Behring, KoP, PAGoogle Scholar
- 5.Adcock D, Bethel MA, Macy PA (2006) Coagulation handbook. Esoterix, Inc. https://www.esoterix.com/sites/esoterix/files/imce/uploads/L3692.pdf. Accessed 21 Mar 2018
- 6.Jones GM, Erdman MJ, Smetana KS, Mohrien KM, Vandigo JE, Elijovich L (2016) 3-Factor versus 4-factor prothrombin complex concentrate for warfarin reversal in severe bleeding: a multicenter, retrospective, propensity-matched pilot study. J Thromb Thrombolysis 42:19–26. https://doi.org/10.1007/s11239-015-1330-3 CrossRefPubMedGoogle Scholar
- 7.Frontera JA, Lewin JJ 3rd, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM, del Zoppo GJ, Kumar MA, Peerschke EI, Stiefel MF, Teitelbaum JS, Wartenberg KE, Zerfoss CL (2016) Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care 24:6–46. https://doi.org/10.1007/s12028-015-0222-x CrossRefPubMedGoogle Scholar
- 10.Devine B (1974) Gentamicin therapy. DICP Ann Pharmacother 8:650–655Google Scholar
- 12.Sarode R, Milling TJ Jr, Refaai MA, Mangione A, Schneider A, Durn BL, Goldstein JN (2013) Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 128:1234–1243. https://doi.org/10.1161/CIRCULATIONAHA.113.002283 CrossRefPubMedGoogle Scholar
- 14.Shingina A, Barkun AN, Razzaghi A, Martel M, Bardou M, Gralnek I, Investigators R (2011) Systematic review: the presenting international normalised ratio (INR) as a predictor of outcome in patients with upper nonvariceal gastrointestinal bleeding. Aliment Pharmacol Ther 33:1010–1018. https://doi.org/10.1111/j.1365-2036.2011.04618.x CrossRefPubMedGoogle Scholar
- 15.Jairath V, Kahan BC, Stanworth SJ, Logan RF, Hearnshaw SA, Travis SP, Palmer KR, Murphy MF (2013) Prevalence, management, and outcomes of patients with coagulopathy after acute nonvariceal upper gastrointestinal bleeding in the United Kingdom. Transfusion 53:1069–1076. https://doi.org/10.1111/j.1537-2995.2012.03849.x CrossRefPubMedGoogle Scholar